New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), ...

Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. Next up, the complement inhibitor—which AZ ...

Ultomiris (ravulizumab-cwvz) is a prescription drug that treats certain rare inflammatory conditions in some people. Learn about dosage, side effects, and more.

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works.

International Stocks to Buy as MAGA Reshapes the Market In volatile markets, the benefits of diversification shine brightly. A diversified portfolio means spreading your capital across a variety of ...

Date 2025-02-11 07:45:57 (MENAFN - EIN Presswire) The Business Research Company Ultomiris Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 ...

Ultomiris can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects last longer than ...

Ultomiris (ravulizumab-cwvz) is a prescription drug that’s used to treat myasthenia gravis and other conditions. Ultomiris’s cost may depend on factors such as your dosage and whether you have ...

Ultomiris was added to AstraZeneca’s portfolio with the July 2021 acquisition of Alexion. The drug recorded sales of $2.97 billion in 2023, up 52% at constant exchange rates. Ultomiris sales are ...